Susan Krashinsky Robertson, a Globe business reporter, shares her insights on Librela, the controversial arthritis drug for dogs. Some pet owners celebrate its effects, claiming happier, more comfortable pets. However, troubling cases of adverse reactions, including severe lethargy and even death, raise serious concerns. Krashinsky discusses her interviews with pet owners and veterinarians, revealing a critical divide about the drug's safety and the need for better communication in veterinary care. The growing popularity of Librela prompts a closer examination of its risks and regulatory practices.
While Librela is marketed as a safe and effective treatment for dog arthritis, many owners report severe adverse reactions post-administration, raising safety concerns.
The communication gap regarding Librela's potential risks has led to owner frustration and regret, underscoring the importance of informed consent in veterinary treatments.
Deep dives
The Role and Function of LaBrella
LaBrella is a veterinary drug designed to alleviate pain in pets, primarily for conditions like arthritis. It was approved in Canada and specifically targets nerve growth factors that send pain signals to the brain, essentially blocking these signals to provide relief. This medication is administered via monthly injections, costing around $100 per shot, and is considered an alternative to traditional non-steroidal anti-inflammatory drugs (NSAIDs), which can have adverse effects on older pets. LaBrella’s popularity has surged alongside the increase in pet ownership during the COVID-19 pandemic, leading to significant sales growth for its manufacturer, Zoetis.
Adverse Reactions and Owner Experiences
While many pet owners report positive outcomes with LaBrella, such as significant pain relief and improved quality of life for their pets, others have described alarming health declines post-treatment. Instances of lethargy, vomiting, and in severe cases, loss of mobility have been reported, leading some owners to question the drug's safety. One specific account highlighted a rapid deterioration in a previously healthy dog following treatment, raising concerns among owners about the purported safety of LaBrella. Although adverse reactions can occur with any medication, the variability in individual pet responses has prompted discussion about the need for caution in prescribing the drug.
Need for Informed Consent Among Vets and Owners
Pet owners have expressed frustration over the lack of thorough communications regarding the potential risks associated with LaBrella before its administration. Many owners were led to believe that the drug had minimal side effects and were not adequately informed about possible adverse reactions, which has led to feelings of heartbreak and regret. Additionally, the marketing strategies of Zoetis, which promote the drug for use even in moderate cases of arthritis, have raised ethical concerns among some veterinarians and owners alike. This situation underscores the importance of informed consent, as many owners wished they had been made more aware of the risks to make better-informed decisions regarding their pets' treatment.
Librela, a new drug to treat arthritis pain in dogs, was approved for use in Canada in 2021. In some cases, it was described to owners as a “miracle drug”, with no side effects other than potential soreness and swelling at the injection site. Some owners describe their dogs seeming happier and more comfortable. But others have reported adverse reactions, including lethargy, disorientation, vomiting, and even death. Zoetis, Librela’s parent company, says Librela is safe and was rigorously tested.
Susan Krashinsky Robertson is a business reporter for the Globe. She spoke to eight people whose pets’ health declined after taking Librela. She’s on the show to talk about the promise of Librela, and what she heard from pet owners and veterinarians about the drug.